Cohance Lifesciences Q4FY26 Results: Revenue at ₹2030.50 Cr, Net Profit ₹343.10 Cr
Cohance Lifesciences reported Q4FY26 results with standalone revenue at ₹567.55 Cr and net profit of ₹34.56 Cr. Consolidated revenue stood at ₹619.12 Cr with net profit of ₹8.31 Cr. Full-year standalone revenue was ₹2030.50 Cr and net profit ₹228.71 Cr. Consolidated full-year revenue was ₹2268.55 Cr and net profit ₹150.12 Cr.
The reported decline in financial performance for the quarter and full year indicates a negative impact on the company's profitability and investor sentiment. However, the company is still profitable, suggesting a medium impact.
The company reported a significant decrease in revenue and net profit for both standalone and consolidated results for the quarter and full year ended March 31, 2026, compared to the previous year.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
For the standalone results, the total income from operations for the quarter ended March 31, 2026, was ₹567.55 crore, a decrease from ₹768.57 crore in the same quarter last year. The net profit for the quarter after tax was ₹34.56 crore, down from ₹122.77 crore year-on-year. For the full year ended March 31, 2026, total income from operations stood at ₹2030.50 crore, a decrease from ₹2504.43 crore in FY25. The net profit after tax for the full year was ₹228.71 crore, down from ₹491.18 crore in FY25.
On a consolidated basis, the total income from operations for the quarter ended March 31, 2026, was ₹619.12 crore, down from ₹840.42 crore in the corresponding quarter of the previous year. The consolidated net profit after tax for the quarter was ₹8.31 crore, a significant decrease from ₹117.15 crore in the same quarter last year. For the full year ended March 31, 2026, consolidated total income from operations was ₹2268.55 crore, down from ₹2608.50 crore in FY25. The consolidated net profit after tax for the full year was ₹150.12 crore, a decrease from ₹484.24 crore in FY25.
Earnings per share (EPS) on a standalone basis for the quarter ended March 31, 2026, was ₹0.90 (basic and diluted), compared to ₹3.22 (basic and diluted) in the prior year quarter. For the full year, standalone EPS was ₹5.98 (basic and diluted), down from ₹12.89 (basic and diluted) in FY25.
Consolidated EPS for the quarter ended March 31, 2026, was ₹0.51 (basic and diluted), down from ₹3.16 (basic and diluted) in the prior year quarter. For the full year, consolidated EPS was ₹4.69 (basic and diluted), down from ₹12.79 (basic and diluted) in FY25.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.